Evidence map›Paper›PMID 38727824›Full record

ArticlePediatric cardiology2025

Selexipag Dosing Strategies for Pediatric Patients with Pulmonary Arterial Hypertension.

Madeline Grossman, Stephen Walker, E Zachary Ramsey

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Madeline GrossmanDepartment of Pharmacy Services, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA. grossmanm3@chop.edu.
Stephen WalkerDivision of Pulmonary Hypertension, Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
E Zachary RamseyDepartment of Pharmacy Services, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This retrospective chart review of patients less than 18 years old with pulmonary arterial hypertension (PAH) receiving selexipag was conducted to describe selexipag dosing practices, impact on concomitant PAH therapies, and the safety and efficacy of selexipag. Twenty-seven patients aged 1-17 years started a median dose of oral selexipag 100 µg twice daily. Therapy was increased by a median of 100 µg twice daily every 6 days to a maximally tolerated median dose of 800 µg twice daily. All 24 patients on another prostacyclin derivative were able to discontinue therapy at their maximum tolerated selexipag dose; other concomitant PAH therapies did not change. Changes in echocardiogram data and 6-MWT results were variable. No patients discontinued selexipag; four patients received decreased doses due to flushing (n = 1), drug interactions (n = 2), or increased frequency of nose bleeds (n = 1).

Indexed as

AcetamidesAntihypertensive AgentsHypertension, PulmonaryPulmonary Arterial HypertensionPyrazinesAdolescentChildChild, PreschoolDose-Response Relationship, DrugFemaleHumansInfantMaleRetrospective StudiesTreatment OutcomeAcetamidesAntihypertensive AgentsPyrazinesselexipagPediatricsProstacyclin derivativeProstacyclin receptor agonistPulmonary hypertensionSelexipag

Identifiers

PMID38727824

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.